Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach.
Fameli A, Nardone V, Shekarkar Azgomi M, Bianco G, Gandolfo C, Oliva BM, Monoriti M, Saladino RE, Falzea A, Romeo C, Calandruccio ND, Azzarello D, Giannicola R, Pirtoli L, Giordano A, Tassone P, Tagliaferri P, Cusi MG, Mutti L, Botta C, Correale P. Fameli A, et al. Among authors: pirtoli l. Front Oncol. 2022 Sep 14;12:911579. doi: 10.3389/fonc.2022.911579. eCollection 2022. Front Oncol. 2022. PMID: 36185285 Free PMC article.
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab.
Giannicola R, D'Arrigo G, Botta C, Agostino R, Del Medico P, Falzea AC, Barbieri V, Staropoli N, Del Giudice T, Pastina P, Nardone V, Monoriti M, Calabrese G, Tripepi G, Pirtoli L, Tassone P, Tagliaferri P, Correale P. Giannicola R, et al. Among authors: pirtoli l. Mol Clin Oncol. 2019 Jul;11(1):81-90. doi: 10.3892/mco.2019.1859. Epub 2019 May 16. Mol Clin Oncol. 2019. PMID: 31289683 Free PMC article.
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up.
Caraglia M, Correale P, Giannicola R, Staropoli N, Botta C, Pastina P, Nesci A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D, Agostino RM, Strangio A, Azzarello D, Nardone V, Falzea A, Cappabianca S, Bocchetti M, D'Arrigo G, Tripepi G, Tassone P, Addeo R, Giordano A, Pirtoli L, Francini G, Tagliaferri P. Caraglia M, et al. Among authors: pirtoli l. Front Oncol. 2019 Nov 8;9:1102. doi: 10.3389/fonc.2019.01102. eCollection 2019. Front Oncol. 2019. PMID: 31781481 Free PMC article.
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab.
Nardone V, Tini P, Pastina P, Botta C, Reginelli A, Carbone SF, Giannicola R, Calabrese G, Tebala C, Guida C, Giudice A, Barbieri V, Tassone P, Tagliaferri P, Cappabianca S, Capasso R, Luce A, Caraglia M, Mazzei MA, Pirtoli L, Correale P. Nardone V, et al. Among authors: pirtoli l. Oncol Lett. 2020 Feb;19(2):1559-1566. doi: 10.3892/ol.2019.11220. Epub 2019 Dec 16. Oncol Lett. 2020. PMID: 31966081 Free PMC article.
Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade.
Nardone V, Giannicola R, Bianco G, Giannarelli D, Tini P, Pastina P, Falzea AC, Macheda S, Caraglia M, Luce A, Zappavigna S, Mutti L, Pirtoli L, Giordano A, Correale P. Nardone V, et al. Among authors: pirtoli l. Front Oncol. 2021 Jun 14;11:684110. doi: 10.3389/fonc.2021.684110. eCollection 2021. Front Oncol. 2021. PMID: 34195086 Free PMC article.
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis.
Nardone V, Giannicola R, Giannarelli D, Saladino RE, Azzarello D, Romeo C, Bianco G, Rizzo MR, Di Meo I, Nesci A, Pastina P, Falzea AC, Caracciolo D, Reginelli A, Caraglia M, Luce A, Mutti L, Giordano A, Cappabianca S, Pirtoli L, Barbieri V, Tassone P, Tagliaferri P, Correale P. Nardone V, et al. Among authors: pirtoli l. Life (Basel). 2021 Nov 15;11(11):1235. doi: 10.3390/life11111235. Life (Basel). 2021. PMID: 34833111 Free PMC article.
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.
Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, Botta C, Capone F, Lombardi A, Pirtoli L, Tassone P, Ulivieri C, Tagliaferri P, Cusi MG, Caraglia M, Correale P. Martino EC, et al. Among authors: pirtoli l. Cell Death Discov. 2016 Oct 3;2:16025. doi: 10.1038/cddiscovery.2016.25. eCollection 2016. Cell Death Discov. 2016. PMID: 27752361 Free PMC article.
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).
Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P. Pastina P, et al. Among authors: pirtoli l. Oncotarget. 2017 Aug 24;8(44):75904-75913. doi: 10.18632/oncotarget.20411. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100279 Free PMC article.
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.
Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, Botta C, Zarone MR, Misso G, Boccellino M, Caraglia M, Giordano A, Paladini P, Tassone P, Tagliaferri P, Cusi MG, Pirtoli L, Correale P. Pastina P, et al. Among authors: pirtoli l. J Thorac Dis. 2017 Sep;9(9):3123-3131. doi: 10.21037/jtd.2017.08.68. J Thorac Dis. 2017. PMID: 29221287 Free PMC article.
132 results